Biotech Stocks Set to Soar - The AI-driven Innovation Phase is Upon Us. BB Biotech is a Promising Core Position!
Reading Time: 1 minute
After infrastructure for AI, we expect the investment trend "Humanoids" as well as the biotech sector to experience AI-driven growth through more innovations. Algorithms today scour millions of biological datasets and discover targets that no one had previously considered. AI is also expected to shorten the preclinical testing phase from 4 to 5 years to 12 to 18 months and help design safer molecules in order to reduce the failure rate. Customized therapies should be easier to develop, as AI can help understand different patient responses to treatments....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
